Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials
- 21 September 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 63 (11), 2482-2485
- https://doi.org/10.1007/s00125-020-05273-7
Abstract
No abstract availableFunding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK106116)
- National Heart, Lung, and Blood Institute (R01-067690)
This publication has 9 references indexed in Scilit:
- Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trialsThe Lancet Diabetes & Endocrinology, 2017
- Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysisDiabetes Care, 2015
- Visit-to-Visit Variability of Blood Pressure and Cardiovascular Disease and All-Cause MortalityHypertension, 2014
- Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE TrialDiabetes Care, 2014
- Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trialThe Lancet, 2010
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesThe New England Journal of Medicine, 2009
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.1998